Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Camrelizumab, Apatinib Plus Hepatic Arterial Infusion Chemotherapy Versus Camrelizumab and Apatinib for Hepatocellular Carcinoma with Portal Vein Invasion: a Randomized, Open-label, Multicentre Trial

Next Previous
Trial Profile

Camrelizumab, Apatinib Plus Hepatic Arterial Infusion Chemotherapy Versus Camrelizumab and Apatinib for Hepatocellular Carcinoma with Portal Vein Invasion: a Randomized, Open-label, Multicentre Trial

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin; Rivoceranib
  • Indications Liver cancer
  • Focus Therapeutic Use

Most Recent Events

  • 21 Jan 2026 Planned End Date changed from 1 Jan 2026 to 1 Jul 2026.
  • 21 Jan 2026 Planned primary completion date changed from 1 Jan 2026 to 1 Jul 2026.
  • 27 Nov 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top